Novo Nordisk and Lumales Bioscience have entered a research collaboration to explore R&D and manufacturing within obesity and other metabolic disorders, the companies announced Wednesday.
The collaboration builds off of research sursphericaling an orally delivered drug for the GI tract that may be manufactured with extra scalability and affordability than a typical small-molecule drug. The initial phases of research will final a few yr, and the two companies will develop molecules using spirulina, a kind of cyanobacteria.
“Novo Nordisk is a world leading metabolic disease company, and we’re thrilled that they share our enthusiasm for brand spanking new strategies for delivering oral biologics,” Lumales’s CEO Brian Finrow, stated in a statement. “This collaboration brings the perfect of two worlds together: Lumales’s expertise in large-scale, affordin a position manufacturing of orally delivered biologic medication and Novo Nordisk’s expertise within the clinical development and commercialization of deal withments for automotivediometabolic disease.”
Financial phrases of the deal weren’t disclosed. — Josh Sullivan
Dana-Farber faucets into Harbour BioMed’s mice platkind in multiyr deal
Harbour BioMed has reached a multiyr agreement with the Dana-Farber Cancer Institute for the development of recent CAR-T cell therapies and bispecific antibodies in cancer deal withment, the company announced Wednesday.
The collaboration will combine Harbour’s transgenic mice platkind with the expertise of Dana-Farber’s scientists in CAR-T cell development.
Harbour used its mice platkind and discovered the antiphysique 47D11 in 2019, which has since been licensed out by AbbVie. In December, the company’s scientists stated that the antiphysique confirmed promise struggleing Covid-19 and variants of the virus.
The Harbour mice professionalgram is predicated on two professionalprietary transgenic mouse platvarieties which have the potential for generating bi and multi-specifics, CAR-Ts or VH doprincipal delivered products.
Eric Smith of the Dana-Farber Cancer Institute stated this within the press release:
“We’re demilded to initiate this collaboration with Harbour BioMed. The complemalestary technology and expertise between Harbour and DFCI will dramatically quicken the interval from novel discovery to developing optimized antiphysique and cellular therapies for clinical translation.” — Josh Sullivan
Because it seems to be to spice up expansion into pet well being, Elanco acquires San Francisco-based pet therapeutic company
Elanco Animal Well being has announced the acquisition of San Francisco-based Kindred Biosciences and with it, three “potential blockbusters within the development section.”
All of KindredBio’s outstanding inventory will likely be acquired at $9.25 a share, making the deal price a total of about $440 million. The company was discovereded in 2012, and brings three professionalgrams that Elanco calls potential dermatology blockbusters which are expected to launch by way of 2025. KindredBio also has a handful of R&D professionalgrams for chronic disorders and unmet wants, including ca9 parvovirus, a excessively contagious virus that affects canines’ fueltrointestinal tract and spreads by way of contaminated stool.
Elanco believes that the acquisition will add another $100 million in revenue to its operations by 2025.
“This excessively complemalestary combination is focused in one of the crucial exciting areas in pet well being, and one the place we see a strategic imperative to construct a differentiated competitive offering,” Jeff Simmons, president and CEO of Elanco, stated in a press release. “It further accelerates our combine shift into pet well being and advertvances our IPP strategy.”
Elanco and KindredBio’s existing relationship began when Kindred licensed out the rights of its late-stage ca9 parvovirus deal withment. — Josh Sullivan
AbSci acquires antiphysique player Totient
A formerly unidentified player that burst onto the scene with a Ginkgo Bioworks deal final September has discovered a brand new residence. The antibody-focused beginup Totient out of the Viva Biotech incubator was acquired by AbSci, the companies announced late Tuesday.
Financial phrases of the deal weren’t disclosed.
Totient emerged from stealth in September with the Ginkgo halfnership, by which they’re attempting to show their alternate technique of generating virus-neutralizing antibodies into a deal withment that might potentially deal with or temporarily prevent Covid-19 infection. The biotech derives its antibodies from what is called tertiary lymphoid structures, or accumulations of immune cells that may kind in locations of peakened inflammation.
In a statement Tuesday, Totient stated it had reconstructed greater than 4,500 antibodies from over 50,000 patients. By combining these with AbSci’s platkind, the pair are going after a brand new set of undisclosed diseases.
“We search forward to scaling our target discovery capabilities to comprehensively de-orphan antibodies and validate new opportunities for drug development,” Totient CEO Deniz Kural stated in a statement.
The purchaseout comes lower than three months after AbSci completed a $125 million crossover spherical and follows a similar acquisition of the AI company Denovium again in January. — Max Gelman